Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-26T12:33:26.177Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessing metabolic syndrome in people with ID (intellectual disabilities) on antipsychotic medication

Published online by Cambridge University Press:  30 July 2014

A. Carballedo ,
A. Doran ,
M. Doyle ,
S. Flavin ,
J. Tyrrel ,
F. Kelly ,
S. Guerin  and
P. Dodd
A. Carballedo*
Affiliation:
St. Michael’s House, Ballymun Road, Dublin, Ireland Institute of Neuroscience, Trinity College Dublin, College Green, Dublin, Ireland
A. Doran
Affiliation:
St. Michael’s House, Ballymun Road, Dublin, Ireland
M. Doyle
Affiliation:
Institute of Neuroscience, Trinity College Dublin, College Green, Dublin, Ireland
S. Flavin
Affiliation:
St. Michael’s House, Ballymun Road, Dublin, Ireland
J. Tyrrel
Affiliation:
St. Michael’s House, Ballymun Road, Dublin, Ireland
F. Kelly
Affiliation:
St. Michael’s House, Ballymun Road, Dublin, Ireland
S. Guerin
Affiliation:
St. Michael’s House, Ballymun Road, Dublin, Ireland
P. Dodd
Affiliation:
St. Michael’s House, Ballymun Road, Dublin, Ireland
*
*Address for correspondence: Dr A. Carballedo, LMC, MRCPsych, MD, Consultant Psychiatrist and Clinical Senior Lecturer, Institute of Neuroscience, Trinity College Dublin, College Green, Dublin D2, Ireland. (Email: [email protected]; [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Aims

To identify whether clinical information routinely collected and recorded on clinical files is available for the identification of metabolic syndrome and to assess the prevalence of risk factors for the syndrome in a sample of people with intellectual disabilities (ID) and mental illness treated with antipsychotic medication.

Methods

A retrospective analysis was performed for 76 adults with ID and comorbid mental illness, for whom treatment with antipsychotic medication was established. Statistical analysis was performed using SPSS 16.0. The Student t-test for parametric data and χ2-test for non-parametrical data were used.

Results

Five of the six criteria for metabolic syndrome were available in all or a high proportion of the files, however no measurement for waist circumference was recorded in any of the files. Aripiprazole appears to be the least risky antipsychotic for metabolic syndrome.

Conclusion

It is important to develop a systematic protocol to record diagnostic variables for metabolic syndrome in at risk populations such as those with ID and mental illness treated with regular antipsychotics.

Type
Original Research
Information
Irish Journal of Psychological Medicine , Volume 31 , Issue 4 , December 2014 , pp. 245 - 251
Copyright
© College of Psychiatrists of Ireland 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alberti, KG, Zimmet, P, Shaw, J (2005). The metabolic syndrome – a new worldwide definition. Lancet 366, 1059–1062.CrossRefGoogle ScholarPubMed
Alberti, KG, Zimmet, P, Shaw, J (2006). Metabolic syndrome – a new worldwide definition. A consensus Statement from the International Diabetes Federation. Diabetic Medicine 23, 469–480.CrossRefGoogle ScholarPubMed
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, 4th edn. American Psychiatric Association: Arlington, VA, USA.Google Scholar
Anderson, PJ, Critchley, JA, Chan, JC, Cockram, CS, Lee, ZS, Thomas, GN, Tomlinson, B (2001). Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. International Journal of Obesity and Related Metabolic Disorder 25, 1782–1788.CrossRefGoogle ScholarPubMed
Angst, F, Stassen, HH, Clayton, PJ, Angst, J (2002). Mortality of patients with mood disorders: follow-up over 34–38 years. Journal of Affective Disorders 68, 167–181.CrossRefGoogle ScholarPubMed
Attux, C, Martini, LC, Elkis, H, Tamai, S, Freirias, A, et al. (2013). A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. BMC Psychiatry 13, 60.CrossRefGoogle ScholarPubMed
Bushe, CJ, Slooff, CJ, Haddad, PM, Karagianis, JL (2013). Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. Journal of Psychopharmacology 27, 358–365.CrossRefGoogle ScholarPubMed
Cooper, SA, Smiley, E, Morrison, J, Allan, L, Williamson, A, Finlayson, J, Jackson, A, Mantry, D (2007). Psychosis and adults with intellectual disabilities. Prevalence, incidence, and related factors. Social Psychiatry and Psychiatric Epidemiology 42, 530–536.CrossRefGoogle ScholarPubMed
Correll, CU, Manu, P, Olshanskiy, V, Napolitano, B, Kane, JM, Malhotra, Ak (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of American Medical Association 302, 1765–1773.CrossRefGoogle ScholarPubMed
Daumit, G, Goff, D, Meyer, J, Davis, V, Nasrallah, H, McEvoy, J, et al. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research 105, 175–187.CrossRefGoogle ScholarPubMed
De Hert, M, Hanssens, L, Van Winkel, R, Wampers, M, Van Eyck, D, Scheen, A, Peuskens, J (2007). A case series: evaluation of the metabolic safety of aripiprazole. Schizophrenia Bulletin 33 823–830.CrossRefGoogle ScholarPubMed
De Hert, M, Schreurs, V, Vancampfort, D, Van Winkel, R (2009). Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8, 15–22.CrossRefGoogle ScholarPubMed
De Hert, M, Vancampfort, D, Correl, CU, Mercken, V, Peuskens, J, Sweers, K, et al. (2011). Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. British Journal of Psychiatry 199, 99–105.CrossRefGoogle ScholarPubMed
De Winter, CF, Bastiaanse, LP, Hilgenkamp, TI, Evenhuis, HM, Echteld, MA (2011). Overweight and obesity in older people with intellectual disability. Research in Developmental Disabilities 33, 398–405.CrossRefGoogle ScholarPubMed
Gazizova, D, Puri, BK, Singh, I, Dhaliwal, R (2012). The overweight: obesity and plasma lipids in adults with intellectual disability and mental illness. Journal of Intellectual Disability Research 56, 895–901.CrossRefGoogle ScholarPubMed
Hilgenkamp, TI, Reis, D, van Wijck, R, Evenhuis, HM (2011). Physical activity levels in older adults with intellectual disabilities are extremely low. Research in Developmental Disabilities 33, 477–483.CrossRefGoogle ScholarPubMed
Hoang, U, Stewart, R, Goldacre, MJ (2011). Mortality after hospital discharge for people with schizophrenia and bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. British Medical Journal 343, d5422.CrossRefGoogle ScholarPubMed
Holt, RIG, Abdelrahman, T, Hirsch, M, Dhesi, Z, George, T, Blincoe, T, et al. (2010). The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. Journal of Psychopharmacology 24, 867–873.CrossRefGoogle ScholarPubMed
International Diabetes Federation (IDF) (2006). The IDF consensus worldwide definition of metabolic syndrome, 2006. Communications Avenue Emile De Mot 19, B-1000 Brussels, Belgium. www.idf.org/metabolic_syndrome.Google Scholar
Luo, B, Yang, Y, Nieman, D, Zhang, Y, Wang, J, Wang, R, Chen, P (2013). A 6-week diet and exercise intervention alters metabolic syndrome risk factors in obese Chinese children aged 11–13 years. Journal of Sport and Health Science 2, 236–241.CrossRefGoogle Scholar
Mackin, P, Bishop, D, Watkinson, H, Gallagher, P, Ferrier, IN (2007). Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. British Journal of Psychiatry 191, 23–29.CrossRefGoogle ScholarPubMed
McCreadie, RG (2003). Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. British Journal of Psychiatry 183, 534–539.Google ScholarPubMed
McIntyre, RS, McCann, SM, Kennedy, SH (2001). Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Canadian Journal of Psychiatry 46, 273–281.CrossRefGoogle ScholarPubMed
McKee, JR, Bodfish, JW, Mahorney, SL, Heeth, WL, Ball, MP (2005). Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. Journal of Clinical Psychiatry 66, 1161–1168.CrossRefGoogle ScholarPubMed
Nesto, RW (2003). The relation of insulin resistance syndromes to risk of cardiovascular disease. Reviews in Cardiovascular Medicine 4, S11–S18.Google ScholarPubMed
Royal College of Psychiatrists (2001). Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities. Royal College of Psychiatrists. London: Gaskell, 2001.Google Scholar
Rummel-Kluge, C, Komossa, K, Schwarz, S, Hunger, H, Schmid, F, Asenjo Lobos, C, Kissling, W, Davis, JM, Leucht, S (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 123, 225–233.CrossRefGoogle ScholarPubMed
Ryan, MC, Collins, P, Thakore, JH (2003). Impaired fasting glucose and elevation of cortisol in drug-naïve first-episode schizophrenia. American Journal of Psychiatry 160, 284–289.CrossRefGoogle Scholar
Sinnema, M, Maaskant, MA, van Schrojenstein Lantman-de Valk, HM, van Nieuwpoort, IC, et al. (2011). Physical health problems in adults with Prader–Willi syndrome. American Journal of Medical Genetics: Part A 155A, 2112–2124.CrossRefGoogle ScholarPubMed
Sukanta, S, Chant, D, McGrath, J (2007). A systematic review of mortality in schizophrenia is the differential mortality gap worsening over time? Archives General Psychiatry 64, 1123–1131.Google Scholar
Tosch, G, Clifton, A, Bachner, M (2011). General physical health advice for people with serious mental illness. Cochrane Database of Systematic Reviews 2, CD008567.Google Scholar
Vinberg, M, Madsen, M, Breum, L, Kessing, LV, Fink-Jensen, A (2012). Metabolic syndrome in a cohort of affectively ill patients, a naturalistic study. Nordic Journal of Psychiatry 66, 142–145.CrossRefGoogle Scholar
Wallace, RA (2004). Risk factors for coronary artery disease among individuals with rare syndrome intellectual disabilities. Journal of Policy and Practice in Intellectual Disabilities 1, 42–51.CrossRefGoogle Scholar